Association Between Costs of Care in Oncology Care Model (OCM)-Defined Episodes and Overall Survival in Multiple Myeloma

The OCM was introduced in 2016 with the goal of improving quality and reducing costs associated with cancer care. Under this framework, practices are incentivized to reduce spending on chemotherapy-centered episodes. A previous study using SEER-Medicare data (2007 –2013) suggested that reducing OCM episode costs in multiple myeloma (MM) may adversely affect patient survival. The present study aimed to evaluate the association between OCM-defined episode costs as well as MM-specific drug costs and overall survival (OS) in MM patients, using more recent data (2010–2015) and included 100% Medicare patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Cynthia Z. Qi, Zhengyi Zhou, Miriam L. Zichlin, Sarah Koenigsberg, James Signorovitch, Zoe Clancy, Ronda Copher, Ruben Niesvizky Source Type: research